FDA warned Pharmacy2Home/LandiCom Holding LTD over unapproved, mislabeled drugs sold online with COVID-19 claims.
What happened
FDA reviewed www.pharmacy2home.com on December 13, 2021 and found the site offered prescription drugs for sale in the U.S. with claims to treat COVID-19 and other diseases. The drugs included chloroquine, oseltamivir, ivermectin, and a “CoronaVirus pack” of ritonavir, lopinavir, ribavirin, and oseltamivir. FDA said there were no approved applications for these products, and their labeling lacked adequate directions for use.
What FDA found
The website sold new drugs without FDA approval for their labeled uses.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]The drugs' labeling did not give adequate directions for safe use by a layperson.
FD&C Act section 502(f)(1) [21 U.S.C. § 352(f)(1)]The company introduced or delivered these unapproved and misbranded drugs into interstate commerce.
FD&C Act sections 301(a) and 301(d) [21 U.S.C. § 331(a), 331(d)]Chloroquine was offered as “Chloroquine (CoronaVirus Covid-19)” even though FDA has not approved chloroquine for COVID-19.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]Ivermectin was offered under “Ivermectin 12mg (Covid/Corona)” even though FDA has not approved ivermectin for COVID-19.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]Oseltamivir and a combination pack were offered with COVID-19 claims even though FDA has not approved those uses.
FD&C Act section 505(a) [21 U.S.C. § 355(a)]
What FDA wants
Within 48 hours, email FDA at the listed addresses with the specific steps taken to address the violations, prevent recurrence, and related documentation. If corrections cannot be completed in that time, explain the delay and the planned completion time.
Who should pay attention
- online pharmacies selling prescription drugs to U.S. consumers
- companies making COVID-19 treatment claims for drug products
- U.S. consumers buying drugs from websites outside normal pharmacy channels
This is a summary. Read the original letter on fda.gov.